Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder

开发一种治疗阿片类药物使用障碍的新型钙通道疗法

基本信息

  • 批准号:
    10684558
  • 负责人:
  • 金额:
    $ 32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-07-15 至 2024-06-30
  • 项目状态:
    已结题

项目摘要

Vivreon Biosciences, LLC 4940 Carroll Canyon Rd., Ste. 110 San Diego, CA 92121 milton@vivreonbiosciences.com NIDA RFA-DA-23-021 Project Summary Opioid use disorder (OUD) is the chronic use of opioids that causes clinically significant distress or impairment. Most hospitalized patients admitted to the trauma unit or intensive care unit (ICU) receive opioids, commonly as part of analgesia and sedation regimens. Repeated opioid exposure produces behavioral sensitization that contributes to drug craving, opioid-induced hyperalgesia (OIH), and withdrawal symptoms. Opioid dependence can be expected in hospitalized patients who have received lengthy opioid dose regimens, and patients are at significant risk of continuing opioid use following discharge. Inpatient stays are often extended to taper dosages and wean patients off opioids, yet these patients remain at increased risk of opioid dependence, withdrawal, and OUD. This cycle of opioid treatment, opioid dependence, opioid tapering, and potential for developing OUD upon discharge represents an urgent unmet medical need that contributes to the opioid pandemic. A small molecule therapeutic that prevents opioid dependence would reduce the length of hospital stays, improve patient outcomes, reduce the risk of OUD, and significantly reduce the cost of care. Vivreon Biosciences intends to address this unmet need by developing a non-opioid new chemical entity (NCE) for prevention of opioid dependence to combat OUD. Tissue damaging microgliosis, the shift of quiescent CNS microglia towards inflammatory behaviors in response to specific signals such as opioid receptor (OR) activation, is documented to be associated with OUD. Therapeutic prevention of inflammatory microgliosis is an innovative approach to preventing the development of opioid dependence. Central nervous system microglial cells are activated by ORs and support inflammatory microglial polarization. We have demonstrated that our candidate therapeutic blunts multiple dimensions of morphine-induced behavioral adaptations. In this Fast Track SBIR project Vivreon will build a full preclinical development program around our Lead VV molecule to treat OUD. In Phase I we will develop dose-response metrics in a mouse model of opioid dependence with multiple readouts and dose-range finding studies to establish therapeutic window indices for two therapeutic compounds. This will allow selection of the most promising Lead compound for further development. Successful Lead selection will justify entering full development studies in Phase II. These studies will encompass standard small molecule Investigational New Drug (IND) efforts including ADME/PK, toxicology and manufacturing studies to de-risk the Lead. Successful conclusion of the project will yield an attractive package that is enticing to third party investors able to provide the financial support required for advancement of the Lead into clinical validation.
Vivreon Biosciences,LLC 4940卡罗尔峡谷路,Ste. 110 San Diego,CA milton@vivreonbiosciences.com NIDA RFA-DA-23-021 项目摘要 阿片类药物使用障碍(OUD)是阿片类药物的长期使用,导致临床显着的痛苦或损害。 大多数进入创伤病房或重症监护病房(ICU)的住院患者接受阿片类药物,通常作为 镇痛和镇静的一部分。反复暴露于阿片类药物会产生行为敏感, 导致药物渴求、阿片样物质诱导的痛觉过敏(OIH)和戒断症状。阿片类药物依赖 在接受长期阿片类药物给药方案的住院患者中, 出院后继续使用阿片类药物的重大风险。住院时间通常延长到逐渐减少剂量 并使患者戒断阿片类药物,但这些患者仍然存在阿片类药物依赖,戒断和 OUD。阿片类药物治疗、阿片类药物依赖、阿片类药物逐渐减少以及在治疗后发生OUD的可能性的循环 出院是一种未得到满足的紧急医疗需求,助长了类阿片大流行。小分子 预防阿片类药物依赖的治疗方法将减少住院时间,改善患者 结果,降低OUD的风险,并显着降低护理成本。Vivreon Biosciences打算 通过开发用于预防阿片类药物的非阿片类药物新化学实体(NCE)来解决这一未满足的需求 依赖于对抗OUD。 组织损伤性小胶质细胞增生,静止的CNS小胶质细胞向炎症行为的转变 阿片受体(OR)激活等特定信号与OUD相关。 炎性小胶质细胞增生症的治疗性预防是预防炎性小胶质细胞增生症发展的创新方法。 阿片类药物依赖中枢神经系统小胶质细胞被OR激活并支持炎症反应 小胶质细胞极化。我们已经证明,我们的候选治疗钝化了多个维度, 吗啡诱导的行为适应在这个快速通道SBIR项目中,Vivreon将建立一个完整的临床前 围绕我们的Lead VV分子开发计划,以治疗OUD。在第一阶段,我们将开发剂量反应 在阿片类药物依赖小鼠模型中使用多个读数和剂量范围探索研究, 建立两种治疗化合物的治疗窗指数。这将允许选择最 有前途的先导化合物。成功的Lead选择将证明进入完整的 第二阶段的发展研究。这些研究将包括标准的小分子研究性新 药物(IND)工作,包括ADME/PK、毒理学和生产研究,以降低电极导线的风险。成功 该项目的结束将产生一个有吸引力的一揽子计划,吸引第三方投资者能够提供 将电极导线推进临床确认所需的财务支持。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Milton L Greenberg其他文献

Milton L Greenberg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Milton L Greenberg', 18)}}的其他基金

Development of a Novel Calcium Channel Therapeutic for the Treatment of Asthma
开发治疗哮喘的新型钙通道疗法
  • 批准号:
    10603554
  • 财政年份:
    2023
  • 资助金额:
    $ 32万
  • 项目类别:
IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy
新型 Ca2 通道治疗药物的 IND 毒理学研究可改善与检查点抑制剂免疫治疗相关的结果
  • 批准号:
    10483840
  • 财政年份:
    2022
  • 资助金额:
    $ 32万
  • 项目类别:
Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
CRAC 通道抑制剂治疗阿尔茨海默病的临床前表征
  • 批准号:
    10837680
  • 财政年份:
    2022
  • 资助金额:
    $ 32万
  • 项目类别:
Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
CRAC 通道抑制剂治疗阿尔茨海默病的临床前表征
  • 批准号:
    10483916
  • 财政年份:
    2022
  • 资助金额:
    $ 32万
  • 项目类别:
Development of a Novel CRAC Channel Therapeutic for the Treatment of Primary Hyperhidrosis
开发用于治疗原发性多汗症的新型 CRAC 通道疗法
  • 批准号:
    10546998
  • 财政年份:
    2022
  • 资助金额:
    $ 32万
  • 项目类别:
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis
VV8220 的预开发,一种针对溃疡性结肠炎的肠道选择性 CRAC 通道疗法
  • 批准号:
    10484704
  • 财政年份:
    2022
  • 资助金额:
    $ 32万
  • 项目类别:
Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
CRAC 通道抑制剂治疗阿尔茨海默病的临床前表征
  • 批准号:
    10704746
  • 财政年份:
    2022
  • 资助金额:
    $ 32万
  • 项目类别:
Predevelopment of VV8321, a Novel CRAC Channel Therapeutic for the Treatment of Osteoarthritis
VV8321 的预开发,一种用于治疗骨关节炎的新型 CRAC 通道疗法
  • 批准号:
    10383630
  • 财政年份:
    2021
  • 资助金额:
    $ 32万
  • 项目类别:
Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder
小胶质细胞 CRAC 通道作为阿片类药物使用障碍新药物靶点的研究
  • 批准号:
    10338665
  • 财政年份:
    2021
  • 资助金额:
    $ 32万
  • 项目类别:
Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy
预先开发 VV2003(一种新型 CRAC 通道抑制剂),以改善与检查点抑制剂免疫疗法相关的结果
  • 批准号:
    10076485
  • 财政年份:
    2020
  • 资助金额:
    $ 32万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 32万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 32万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 32万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 32万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 32万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 32万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了